Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure
- 1 June 2000
- journal article
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 1 (2) , 147-150
- https://doi.org/10.3317/jraas.2000.018
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?Heart, 1999
- Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the losartan heart failure survival study-ELITE IIJournal of Cardiac Failure, 1999
- Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonismJournal of the American College of Cardiology, 1999
- Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart FailureCirculation, 1999
- Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitorThe American Journal of Cardiology, 1994
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatmentJournal Of Hypertension, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.Circulation, 1991